Name James Wilson | Role Scientist | |
James wilson s explique des raisons de sa defaites contre quarteron
James M. Wilson is an American geneticist and medical researcher at the University of Pennsylvania, known for his work on gene therapy, where he was regarded as one of the field's most prominent researchers until ethical concerns arose around the death of a patient in one of his trials.
Contents
- James wilson s explique des raisons de sa defaites contre quarteron
- James wilson puts his nerves aside to fight for a chair six chair challenge the x factor uk 2016
- Biography
- OTD clinical trial
- References
James wilson puts his nerves aside to fight for a chair six chair challenge the x factor uk 2016
Biography
Wilson earned his BA in chemistry at Albion College in 1977, and his MD and PhD at the University of Michigan in 1984, where he studied the genetics of Lesch-Nyhan syndrome. He did a residency in internal medicine at Mass General Hospital and a postdoctoral fellowship at MIT with Richard Mulligan.
As of 2017, he is the director of the University of Pennsylvania Gene Therapy Program and Orphan Disease Center. His research interests include genetic disorders of lipid metabolism, and gene therapy for dyslipidemias, coronary artery disease, congestive heart failure, pandemic viruses, lysosomal storage diseases, and editing delivery technology.
OTD clinical trial
In 1997, Wilson, Steven Raper, and Mark Batshaw, all physicians at the University of Pennsylvania, began enrolling patients in a clinical trial using experimental gene therapy to treat ornithine transcarbamylase deficiency. In 1998, after a patient experienced liver toxicity as a side effect of the treatment, they altered the clinical trial agreement to allow patients to continue receiving treatment after experiencing liver toxicity. As the administered doses increased, subsequent patients experienced liver toxicity on a regular basis.
In 1999, Jesse Gelsinger died after receiving a gene therapy treatment. Due to his blood ammonia levels being above the maximum allowed for the study, he should not have been allowed to enroll. Further investigation showed improper consent forms and that Wilson had significant financial stakes in the success of the trial. Wilson agreed to a five-year ban on participating in clinical trial research.